AstraZeneca Taps Pieris For Inhaled Asthma Anticalins
Executive Summary
AstraZeneca is to pay $57.5m to get its hands on biotech Pieris Pharmaceuticals' Anticalin technology to bolster its early stage respiratory portfolio, with a lead product candidate already being prepared for Phase I.
You may also be interested in...
Pieris Looks For Way Out After AstraZeneca Exits Respiratory Collaboration
The US biotech is hoping to either partner off its wholly owned pipeline or become a target for an acquisition or merger after AstraZeneca’s asthma exit left it with dwindling cash, and a need to cut costs.
Pieris And Seattle Strike IO Deal
Pieris secures another deal for its novel Anticalin technology – this time with Seattle in immuno-oncology.
End Of The Line For AstraZeneca’s Tralokinumab In Asthma
Another Phase III failure looks likely to spell the end for AstraZeneca’s tralokinumab in severe uncontrolled asthma. The company’s eyes are now firmly fixed on benralizumab.